Scarica l'app Stockscreener
6.18
5.28%
0.31
Dopo l'orario di chiusura:
6.20
0.02
+0.32%
Precedente Chiudi:
$5.87
Aprire:
$6.08
Volume 24 ore:
294.68K
Relative Volume:
1.31
Capitalizzazione di mercato:
$267.44M
Reddito:
-
Utile/perdita netta:
$-293.42M
Rapporto P/E:
-0.2306
EPS:
-26.8031
Flusso di cassa netto:
$-13.51M
1 W Prestazione:
+14.02%
1M Prestazione:
-21.07%
6M Prestazione:
+146.22%
1 anno Prestazione:
+318.98%
Intervallo 1D:
$5.80
$6.65
Intervallo di 1 settimana:
$5.13
$6.65
Portata 52W:
$1.30
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Nome
Minerva Neurosciences Inc
Settore
Industria
Telefono
617-600-7373
Indirizzo
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
6.18 | 254.02M | 0 | -293.42M | -13.51M | -26.80 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Iniziato | BTIG Research | Buy |
| 2019-10-02 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-25 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-31 | Iniziato | H.C. Wainwright | Buy |
| 2017-09-01 | Iniziato | Citigroup | Buy |
| 2017-03-06 | Ripresa | Jefferies | Buy |
| 2016-05-12 | Ripresa | Jefferies | Buy |
Mostra tutto
Minerva Neurosciences Inc Borsa (NERV) Ultime notizie
NERV Initiates Coverage On Citizens -- Rating Set to Market Outp - GuruFocus
Minerva stock wins New Outperform at Citizens (NERV:NASDAQ) - Seeking Alpha
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates Minerva Neurosciences stock at outperform, $14 target By Investing.com - Investing.com India
Citizens initiates Minerva Neurosciences stock at outperform, $14 target - Investing.com
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences - Yahoo Finance
Retail Surge: Is Minerva Neurosciences Inc stock technically oversold2026 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Minerva Neurosciences (NASDAQ: NERV) proxy: charter amendments, say‑on‑pay vote - Stock Titan
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - The Globe and Mail
Minerva Neurosciences, Inc. Files Form 8-K with SEC – Company Information and Key Details (April 6, 2026) 14 - Minichart
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
Minerva Neurosciences sets June 2026 date for annual stockholder meeting By Investing.com - Investing.com Australia
Minerva Neurosciences sets June 2026 date for annual stockholder meeting - Investing.com
Minerva Neurosciences sets June 3, 2026 annual meeting; stockholder notice deadlines announced - TradingView — Track All Markets
Minerva Neurosciences (NASDAQ: NERV) sets 2026 meeting and proposal deadlines - Stock Titan
Ideas Watch: Is Minerva Neurosciences Inc stock a hidden gemPortfolio Gains Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Minerva Neurosciences Appoints New Chief Business Officer, Counsel - The Globe and Mail
Minerva Neurosciences names Jim O’Connor as chief business officer By Investing.com - Investing.com Canada
Minerva Announces Leadership Transition - Bitget
Minerva announces leadership transition - MarketScreener
Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO Following Leadership Transition - geneonline.com
Minerva Neurosciences names Jim O’Connor as chief business officer - Investing.com
Leadership shift at Minerva Neurosciences (NASDAQ: NERV) as O’Connor joins - Stock Titan
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan
Minerva Neurosciences (NERV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NERV - MarketBeat
NERV Technical Analysis & Stock Price Forecast - Intellectia AI
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Tr - GuruFocus
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Treatment - GuruFocus
Federated Hermes sells 3,658 shares of NERV common stock (NASDAQ: NERV) - Stock Titan
Federated Hermes sells 97,549 NERV shares (NASDAQ: NERV) in Form 144 notice - Stock Titan
NERV (NASDAQ: NERV) Form 144 shows 156,410-share sale, 650,000 offered - Stock Titan
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - The Manila Times
Profit Recap: What is the earnings history of Minerva Neurosciences Inc2026 Bull vs Bear & Detailed Earnings Play Strategies - baoquankhu1.vn
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia - Seeking Alpha
Guidance Update: Can Minerva Neurosciences Inc stock outperform in a bear market2026 Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Short Interest in Minerva Neurosciences, Inc (NASDAQ:NERV) Grows By 27.8% - MarketBeat
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst - MSN
Minerva Neurosciences : Olanzapine added to Roluperidone, in patients with negative symptoms (NS) of schizophrenia - marketscreener.com
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - Investing News Network
Minerva Neurosciences Presents Data from its Open-label - globenewswire.com
Market Overview: Can Minerva Neurosciences Inc continue delivering strong returns2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms - MarketBeat
[EFFECT] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Minerva Neurosciences, IncCommon Stock (NQ: NERV - markets.chroniclejournal.com
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Minerva Neurosciences (NERV) - The Globe and Mail
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings - MarketBeat
Minerva Neurosciences shareholders approve key governance measures - MSN
Minerva Neurosciences Inc Azioni (NERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):